NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

Here on this YouTube audio from 2024 @ 32 minutes in Dr. Liau seems clear that DCVAX-L is not ready for commercialization. She just hopes that it can be placed in the Right to Try category to compile real word data for proof of efficacy. “Next steps are studying MOA and enhancing the efficacy. She says Seems to be a signal of efficacy. She hopes some day it could be FDA approved and speaks of subsequent trials as further proof of efficacy. She foresees another randomized trial only with the right sponsor. Says nothing about commercialization with MHRA only Compassionate use in the UK. Says Needs more validation of efficacy. More combo testing. Patients doing off label with less proof of efficacy so why not L? Speaks about Right to Try.

“May 2024 Neurology Recall: Topics in Neuro-Oncology”